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Background: Rhabdomyolysis is an uncommon side effect of trabectedin which is used for the second line therapy
of metastatic sarcoma after anthracycline and ifosfamide failure. This side effect may be due to pharmacokinetic
interactions caused by shared mechanisms of metabolism involving the cytochrome P450 (CYP) system in the liver.
Here, for the first time in literature, we describe the unexpected onset of heavy toxicity, including rhabdomyolysis,
after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was
taking an alternative herbal medicine suspected of triggering this adverse event.
Case presentation: This is the case of a 56 year old Caucasian man affected by a relapsed de-differentiated
liposarcoma who, after the fourth cycle of second-line chemotherapy with trabectedin, complained of sudden
weakness, difficulty walking and diffuse muscle pain necessitating complete bed rest. Upon admission to our ward
the patient showed grade (G) 4 pancytopenia and a marked increase in liver lytic enzymes, serum levels of
myoglobin, creatine phosphokinase (CPK) and lactate dehydrogenase. No cardiac or kidney function injuries were
present. Based on these clinical and laboratory features, our conclusive diagnosis was of rhabdomyolysis induced by
trabectedin.
The patient did not report any trauma or muscular overexertion and no co-morbidities were present. He had not
received any drugs during treatment with trabectedin, but upon further questioning the patient informed us he
had been taking a folk medicine preparation of chokeberry (Aronia melanocarpa) daily during the last course of
trabectedin and in the 2 subsequent weeks.
One week after hospitalization and cessation of intake of chokeberry extract, CPK and other markers of myolysis
slowly returned to standard range, and the patient noted a progressive recovery of muscle strength.
The patient was discharged on day 14 when a blood transfusion and parenteral hydration gradually lowered
general toxicity. Progressive mobilization of the patient was obtained as well as a complete normalization of the
laboratory findings.
Conclusions: The level of evidence of drug interaction leading to the adverse event observed in our patient was 2
(probable). Thus our case underlines the importance of understanding rare treatment-related toxicities such as
trabectedin-induced rhabdomyolysis and the possible role of the drug-drug interactions in the pathogenesis of this
rare side effect. Furthermore, this report draws attention to a potential problem of particular concern, that of
nutritional supplements and complementary and alternative drug interactions. These are not widely recognized and
can cause treatment failure.
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Despite aggressive surgery and adjuvant radiotherapy,
more than half of patients with soft tissue sarcoma
develop a locally advanced or metastatic disease [1]. Un-
fortunately there are very few active drugs for these
patients. By far the most relevant change in this scenario
is trabectedin, a drug isolated from the marine micro-
organism Ecteinascidia turbinate. Trabectedin was ap-
proved in Europe in 2007 as a single agent for second-line
therapy of soft tissue sarcomas, and its activity is mainly
relevant in liposarcoma and leiomyosarcoma [2].
While adverse reactions to trabectedin treatment such
as neutropenia and liver function test alterations are
well-known, more education and data are needed on
some of the rare side effects mediated by this drug, such
as the potential induction of rhabdomyolysis. A recent
comprehensive safety analysis confirmed the uncommon
occurrence of this side effect and also pointed out the
need to avoid pharmacokinetic interactions with con-
comitant drugs caused by shared mechanisms of me-
tabolism by the cytochrome P450 (CYP) system in
the liver [3].
We describe here the unexpected onset of heavy
toxicity including rhabdomyolysis after the fourth
course of trabectedin in a patient with retroperitoneal
liposarcoma who at the same time was taking an al-
ternative herbal medicine suspected of triggering this
adverse event. This report calls attention to a poten-
tial problem of particular concern, that of herbal-drug
interaction. This problem is not widely recognized
and can cause treatment failure in patients without
an immediately obvious clinical modification.
Case presentation
This is the case of a 56 year old Caucasian man from
Montenegro whose cancer history began in April 2009
after the appearance of progressive abdominal pain due to
a retroperitoneum mass measuring 5 × 8 cm. The patient’s
past medical record showed no relevant illness. He was an
ex heavy smoker and did not drink alcohol or use illicit
drugs. In May 2009 he underwent surgical removal of the
abdominal mass achieving a complete margin negative
(R0) resection. Histological findings of lesion specimens
highlighted a low-grade de-differentiated liposarcoma. He
then began follow-up. In November 2011 a computed
tomography (CT) scan detected a new retroperitoneal le-
sion measuring 5 × 10 cm whose imaging features clearly
suggested relapsed liposarcoma. He therefore underwent
another radical surgery and the second histological exam-
ination supported the diagnosis of G2 de-differentiated
liposarcoma with myxoid areas. Fluorescence in situ
hybridization (FISH) analysis for oncogene murine double
minute 2 (MDM2) status highlighted the amplification as
highly specific diagnostic markers [4].After only three months, a new recurrence occurred
and owing to the brief relapse-free time he was not con-
sidered suitable for additional surgery. Accordingly, he
was treated with chemotherapy including three cycles of
doxorubicin followed by three cycles of ifosfamide. In
spite of chemotherapy, the lesion progressed rapidly
reaching 16 × 10 cm and extending into the pre-aortic
seat of the retro-peritoneum space. In April 2012 the
patient was referred to our Institute and underwent
second line chemotherapy with trabectedin at a dose
of 1.5 mg/m [2], administered as a 24-hour continuous
intravenous infusion repeated every 21 days. Intravenous
premedication was normally used before trabectedin
administration and included dexamethasone 12 mg,
palenosetron 250 mcg and chlorphenamine maleate 10
mg. Due to the previous chemotherapy treatment, we
decided to use prophylactic peg-G-CSF (granulocytes col-
ony stimulating factor) administered the day after
chemotherapy. Chemotherapy was well tolerated for
the first three courses, and no abnormalities regarding
hematological, liver and muscle enzyme levels were
present. At this time, the patient’s Eastern Cooperative
Oncology Group (ECOG) performance status was 0 and
stable disease was documented by an abdominal CT scan
examination. Due to no alternative therapeutic options,
we decided to continue chemotherapy with trabectedin.
Two weeks after the fourth cycle of chemotherapy,
the patient began to complain of sudden weakness,
difficulty walking and diffuse muscle pain. Some days
after he was confined to complete bed rest as the
muscle pain became unbearable. For these reasons,
the patient was urgently admitted to our ward and
parenteral hydration and symptomatic therapy were
initiated. Laboratory tests found G4 pancytopenia and
a marked increase in liver lytic enzymes. At the same
time, serum levels of myoglobin, creatine phosphoki-
nase (CPK) and lactate dehydrogenase (LDH) showed
an increase respectively of eighteen, eight and four
times over the upper normal range value (Table 1).
The absence of abnormalities on electrocardiogram
and echocardiography ruled out cardiac etiology for
the increased serum level of these enzymes. No kid-
ney function injury was present. Due to these clinical
and laboratory features, our conclusive diagnosis was
of rhabdomyolysis induced by trabectedin.
As the patient had this unusual muscular side effect
after the fourth cycle of trabectedin, we explored pos-
sible sources that could trigger the potential trabectedin-
induced rhabdomyolysis. He did not report any trauma
or muscular overexertion. Due to the absence of co-
morbidity, the patient had not received any other
drugs during treatment with trabectedin. After further
questioning in a non-threatening fashion, the patient
informed us that he had been taking a commercial
Table 1 Behavior of laboratory parameters related to rhabdomyolysis starting from the first day of chemotherapy
Laboratory test Normal range Day 1 Day 13 Day 15 Day 17 Day 20
White blood cell count 4-10 × 103/μl 3,6 3,2 2,5 3,6 2,9
Absolute neutrophils 1,7-7,6 × 103/μl 1,6 2,3 1,3 1,1 1,6
Hemoglobin 13,5-17,5 g/dl 12,2 7,5 8,8 9,1 9,3
Platelets 150-450 ×103/μl 335 77 162 367 389
ALT 0-41 U/L 36 449 294 89 44
AST 0-40 U/L 34 504 176 31 21
LDH 135-225 U/L 165 986 543 286 201
Myoglobin 28-72 ng/ml Not tested 1349 981 148,5 83,32
CPK 0-190 U/L Not tested 1619 1126 217 107
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melanocarpa) daily during the last course of trabectedin
and in the 2 weeks after.
One week after hospitalization and stopping intake of
chokeberry extract, CPK and other markers of myolysis
slowly returned to standard range and the patient felt a
progressive recovery of muscle strength.
The patient was discharged on day 14 when blood
transfusion and parenteral hydration gradually reduced
general toxicity. A progressive mobilization of the pa-
tient was obtained as well as a complete normalization
of the laboratory findings (Table 1).
Discussion and conclusions
Among mesenchymal tumors, liposarcoma has proven
to be the most sensitive to the marine alkaloid
trabectedin [2]. This antitumor agent is used in second
line therapy after anthracycline and ifosfamide failure. In
this context, trabectedin acquires a central role in
retroperitoneum liposarcoma which relapses very fre-
quently and exhibits low response to few drugs. The
most common side effects of trabectedin include
myelotoxicity and liver toxicity, mainly in the form of an
increase of transaminase. Rhabdomyolysis is an uncom-
mon side effect of trabectedin with an incidence of 0.5-
0.7% [3,5]. Nevertheless, it can have an important impact
on the morbidity and mortality of patients, and lead to
renal failure due to serum release of toxic muscle cell
components. Even if multivariate analysis does not iden-
tify any predictor factor of rhabdomyolysis developing, it
is mandatory to avoid conditions which could trigger
this occurrence such as direct trauma, seizures, extreme
exertion, body-temperature extremes, muscle hypoxia,
infections (sepsis and severe pneumonia) and endocrine
disorders (hypothyroidism). Rhabdomyolysis is not a
cumulative adverse effect of trabectedin because the
majority of cases happen during the first 3 cycles, but
the mechanism by which it may be caused is unknown.
It is possible to deduce from safety analysis and case re-
ports that a relevant risk issue is pharmacodynamic andpharmacokinetic drug interaction [6]. Beyond the phar-
macodynamic interaction with substances of abuse such
as alcohol and cocaine or medications like statins, con-
comitant treatments with drugs exerting a CYP inhibitor
activity can increase serum trabectedin levels leading to
toxicity. This is because trabectedin is eliminated
through hepatic metabolism and CYP3A4 is the princi-
pal responsible enzyme mediating its degradation [7]. As
known, cancer patients are likely to experience drug
interactions due to the increased number and types of
chemotherapeutic drugs, their combinations in oncology
practice and their narrow therapeutic index, the achieve-
ment of a prolonged life expectancy, and the common
use of a broad range of ancillary medications to prevent
and/or treat cancer-related syndromes and treatment-
induced toxicity [8]. In some cases, a drug interaction
may result from an unexpected source, such as herbs or
vitamins, which most patients do not consider to be
drugs. Given the lack of effectiveness, many cancer
patients treated with conventional therapies also try
'alternative' cancer treatments even when beneficial
effects have not been proven [9]. There are many
challenges related to alternative medication as a treat-
ment for cancer, not the least toxicity related to the
interaction with conventional chemotherapy. Despite
the increasing use of these alternative medications
among cancer patients, the breadth of their side ef-
fects is not always well known and is still seldom
addressed, therefore these patients risk being more
harmed than helped by these compounds [10,11]. In
Table 2 the most common herbal medicines involved
in pharmacokinetic interactions with chemotherapeu-
tic drugs via CYP are reported.
In our patient this “natural foe” was chokeberry
(Aronia melanocarpa) extract derived from the black
fruit of this shrub. This berry has a long tradition in
European and North American folk medicine [19]. It is a
relatively concentrated source of flavonoids such as
quercetin, and is also reported to strongly inhibit
CYP3A4 activity in the liver. Consequently it is capable
Table 2 An overview of the most common herbal
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peutic agents [20]. Furthermore, the polyphenol antho-
cyanins in these berries are proven to have antioxidant
properties which positively influence several risk factors
for cardiovascular disease as well as anti-proliferative or
protective effects against colon cancer [21,22]. Several
other substances such as sorbitol and polyphenols like
laetrile advocated by some as a “cure” or a “preventative”
for cancer are burdened by considerable doubt about
their safety, and there are no proven beneficial effects
for cancer patients [7].
From a clinical-pharmacological point of view, due to
the evidence concerning decreased activities of enzym-
atic markers of CYP after forced feeding of chokeberry
juice [23], the adverse event observed in our patient was
secondary to the herbal-chemotherapy interaction with a
level of evidence of 2 (probable) [24]. However, there are
limitations that deserve to be noted which should be
appropriately handled in future studies: the idiosyn-
cratic nature of trabectedin-related rhabdomyolysis;
the patient’s pharmacokinetic parameters which have
been altered by the cancer and the therapy itself; and
the conceivable re-challenge with trabectedin after
this side effect [25]. Moreover, as the patient took acommercial preparation of chokeberry juice which did
not provide information on the amounts of its com-
pounds, it cannot be excluded that other interactions
might have occurred such as the inhibition of trans-
port mechanisms, the activation of the death receptor
and other unknown mechanisms. Thus these potential
interactions could occur not only with trabectedin but
also with other chemotherapies. The development of
medication databases linked to electronic screening
programs is a useful tool that could help health pro-
fessionals to identify dangerous herbal-drug combina-
tions in the oncology setting [26].
In conclusion, our case underlines the importance of
understanding rare treatment-related toxicities such as
trabectedin-induced rhabdomyolysis and the possible role
of the drug-drug interactions in the pathogenesis of this
rare trabectedin side effect. Furthermore, in the presence
of unexpected toxicity during conventional anticancer
treatment, the simultaneous use by the patient of alterna-
tive drugs should be suspected. So a thorough medication
history, enquiring about nutritional supplements and
over-the-counter drugs, may help raise some red flags
about potential interactions with chemotherapy.
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